



DIVISION OF
CORPORATION FINANCE

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

May 7, 2025

Bruce Jacobs
Chief Financial Officer
Kymera Therapeutics, Inc.
500 North Beacon Street, 4th Floor
Watertown, MA 02472

Re: Kymera Therapeutics, Inc.
Form 10-K for Fiscal Year Ended December 31, 2024
File No. 001-39460

Dear Bruce Jacobs:

We have completed our review of your filings. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Sincerely,

Division of Corporation Finance
Office of Life Sciences